C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I-Reference-Cited by-同舟云学术

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

Published:2012-01-18 Issue:5 Volume:35 Page:568-576
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Reinisch W.¹,Wang Y.²,Oddens B. J.³,Link R.⁴

Affiliation:

1. Division of Gastroenterology and Hepatology; Department of Internal Medicine III; Medical University of Vienna; Vienna; Austria

2. Schering-Plough Corporation; a subsidiary of Merck, Inc.; Global Medical Affairs; Kenilworth; NJ; USA

3. Schering-Plough Corporation; a subsidiary of Merck & Co.; Global Medical Affairs; Oss; The Netherlands

4. Medical Affairs Immunology Europe; Janssen Biologics Europe; Leiden; The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2011.04987.x/fullpdf

Reference19 articles.

1. Epidemiology of inflammatory bowel disease;Loftus;Gastroenterol Clin North Am,2002

2. Mortality and causes of death in patients with chronic inflammatory bowel disease in Gijón, Asturias (Spain);Saro Gismera;Rev Esp Enferm Dig,1999

3. Mortality in inflammatory bowel disease: a population-based cohort study;Card;Gastroenterology,2003

4. Epidemiology of inflammatory bowel disease in Italy;Cottone;Ital J Gastroenterol Hepatol,1999

5. Inflammatory bowel diseases: meeting of the European Crohn's Colitis Organization, 1-3 March 2007, Innsbruck, Austria;Tilg;Expert Opin Ther Targets,2007

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and future application of indigo naturalis in the treatment of ulcerative colitis;Journal of Ethnopharmacology;2025-01

2. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

3. Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial;Digestive and Liver Disease;2024-07

4. Longitudinal Measurements of Blood Biomarkers in Patients with Crohn’s Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure;Journal of Clinical Medicine;2024-02-06

5. Use of double-balloon endoscopy and an endoscopic scoring system to assess endoscopic remission in isolated small bowel Crohn’s disease after treatment with infliximab;Therapeutic Advances in Gastroenterology;2024-01